title: Aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world. It is of important significance to find biomarkers for the prognostic monitoring of HCC. The 14-3-3σ and EZH2 proteins are involved in cell cycle regulation and epigenetic silencing. We herein examined the significance of 14-3-3 σ and EZH2 in HCC (n = 167) by immunohistochemistry, RT-PCR and qRT-PCR. The correlation between 14-3-3σ and EZH2 expression and patients' clinicopathologic features were examined, as was the correlation between 14-3-3σ and EZH2 expression and the prognosis of HCC patients. We found that 14-3-3σ and EZH2 were highly expressed in HCC (71% and 90%), the expression of EZH2, but not 14-3-3σ, is associated with vascular invasion and tumor differentiation (p<0.01). The coexistence of 14-3-3σ and EZH2 overexpression is associated with a relatively unfavorable prognosis (p<0.01), suggesting that aberrant upregulation of 14-3-3σ and EZH2 expression serves as an inferior prognostic biomarker for HCC.
authors.affiliation: Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, P.R. China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Gastrointestinal Surgery, Third Xiangya Hospital, Central South University, Changsha, P.R. China.
authors.forename: Changwei
authors.initials: C
authors.lastname: Lin
authors.affiliation: Department of Gastrointestinal Surgery, Guizhou Provincial People's Hospital, Guiyang, P.R. China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ding
authors.affiliation: Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, P.R. China.
authors.forename: Guoqing
authors.initials: G
authors.lastname: Liao
authors.affiliation: Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, P.R. China.
authors.forename: Bo
authors.initials: B
authors.lastname: Tang
mesh_terms: D048948:14-3-3 Proteins / Q000235:genetics*; D000328:Adult; D000368:Aged; D015415:Biomarkers; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008099:Liver / Q000378:metabolism; D008103:Liver Cirrhosis / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008113:Liver Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D063151:Polycomb Repressive Complex 2 / Q000235:genetics*; D011379:Prognosis; D012372:ROC Curve; D047368:Tumor Burden; D015854:Up-Regulation
chemical_list: D048948:14-3-3 Proteins; D015415:Biomarkers; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2